Cellectis (Cellectis) Dividends per Share : $0.00 (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Cellectis Dividends per Share?

Cellectis's dividends per share for the three months ended in Sep. 2023 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2023 was 0.00. As of today, Cellectis's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Cellectis Dividends per Share Historical Data

The historical data trend for Cellectis's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Dividends per Share Chart

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividends per Share

Get a 7-Day Free Trial

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cellectis's Dividends per Share

For the Biotechnology subindustry, Cellectis's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cellectis's Dividend Yield % falls into.

Cellectis Dividends per Share Calculation

Dividends paid to per common share.

Cellectis (NAS:CLLS) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Cellectis's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.384
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Cellectis Dividends per Share Related Terms

Thank you for viewing the detailed overview of Cellectis's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.